WallStSmart

Netflix Inc (NFLX)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 3% more annual revenue ($46.72B vs $45.18B). NFLX leads profitability with a 24.3% profit margin vs 16.7%. NFLX appears more attractively valued with a PEG of 1.92. NFLX earns a higher WallStSmart Score of 70/100 (B).

NFLX

Strong Buy

70

out of 100

Grade: B

Growth: 8.7Profit: 9.0Value: 9.3Quality: 8.0
Piotroski: 6/9Altman Z: 3.27

SNY

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 6.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NFLXUndervalued (+22.1%)

Margin of Safety

+22.1%

Fair Value

$118.40

Current Price

$92.28

$26.12 discount

UndervaluedFair: $118.40Overvalued
SNYSignificantly Overvalued (-89.7%)

Margin of Safety

-89.7%

Fair Value

$24.79

Current Price

$46.03

$21.24 premium

UndervaluedFair: $24.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NFLX6 strengths · Avg: 9.2/10
Market CapQuality
$385.67B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
42.8%10/10

Every $100 of equity generates 43 in profit

Altman Z-ScoreHealth
3.2710/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
24.3%9/10

Keeps 24 of every $100 in revenue as profit

Operating MarginProfitability
24.5%8/10

Strong operational efficiency at 24.5%

Revenue GrowthGrowth
17.6%8/10

17.6% revenue growth

SNY3 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Market CapQuality
$109.03B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.59B8/10

Generating 1.6B in free cash flow

Areas to Watch

NFLX3 concerns · Avg: 4.0/10
PEG RatioValuation
1.924/10

Expensive relative to growth rate

P/E RatioValuation
35.9x4/10

Premium valuation, high expectations priced in

Price/BookValuation
14.6x4/10

Trading at 14.6x book value

SNY3 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Return on EquityProfitability
6.7%3/10

ROE of 6.7% — below average capital efficiency

PEG RatioValuation
4.322/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : NFLX

The strongest argument for NFLX centers on Market Cap, Return on Equity, Altman Z-Score. Profitability is solid with margins at 24.3% and operating margin at 24.5%. Revenue growth of 17.6% demonstrates continued momentum.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.

Bear Case : NFLX

The primary concerns for NFLX are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : SNY

The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.

Key Dynamics to Monitor

NFLX profiles as a growth stock while SNY is a mature play — different risk/reward profiles.

NFLX carries more volatility with a beta of 1.71 — expect wider price swings.

NFLX is growing revenue faster at 17.6% — sustainability is the question.

NFLX generates stronger free cash flow (1.9B), providing more financial flexibility.

Bottom Line

NFLX scores higher overall (70/100 vs 49/100), backed by strong 24.3% margins and 17.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Netflix Inc

COMMUNICATION SERVICES · ENTERTAINMENT · USA

Netflix, Inc. is an American over-the-top content platform and production company headquartered in Los Gatos, California. Netflix was founded in 1997 by Reed Hastings and Marc Randolph in Scotts Valley, California. The company's primary business is a subscription-based streaming service offering online streaming from a library of films and television series, including those produced in-house.

Visit Website →

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?